Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4 versus 8 infusions of Tepezza in thyroid eye disease with early optimal response
MOH_2026-01-18_015609Phase 4Not yet recruiting
- Sponsor
- פרופסור דפנה לנדאו-פרט
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of teprotumumab in Graves Orbitopathy (GO) (2 arms), sponsored by פרופסור דפנה לנדאו-פרט. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on MOH_2026-01-18_015609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-18_015609.